Management of Castration Resistant Prostate Cancer

• Corporate Author: SpringerLink (Online service)
• Other Authors: Saad, Fred (Editor), Eisenberger, Mario A. (Editor)
• Format: Electronic eBook
• Language: English
• Published: New York, NY : Springer New York : Imprint: Humana Press, 2014.
• Series: Current Clinical Urology,
• Subjects: Medicine.; Interventional radiology.; Oncology.; Urology.; Medicine & Public Health.; Interventional Radiology.

 This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in-depth review of proven therapeutic options, including bone-targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigation are also reviewed. The text provides up-to-date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence-based medicine. As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy. 

 Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities -- Evolution of Clinical States and the Castration Resistant Clinical Paradigm -- Molecular Mechanisms of Prostate Cancer Progression after Castration -- New Imaging Modalities -- Androgen Receptor Biology in Castration Resistant Prostate Cancer -- The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer -- Approaches Targeting Androgen Synthesis (CYP 17 inhibitors) -- Cytotoxic Chemotherapy (Taxanes and Taxane Combinations) -- The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer -- Bone Targeted Therapy: Rationale and Current Status -- Radium-223 and Other Radiopharmaceuticals in Prostate Cancer -- Introduction -- Phase I/II targeted treatments -- Defining Clinical Endpoints in Castration-resistant Prostate Cancer -- Angiogenesis Inhibition in Castration Resistant Prostate Cancer -- Co-targeting Adaptive Survival Pathways -- Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer -- PARP Inhibitors -- Targeting C-Met/VEGF in Castration Resistant Prostate Cancer -- Epigenetics in Castration Resistant Prostate Cancer -- Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype -- Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management -- Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development.